Nearly two months ahead of its July 25 PDUFA date, Amgen Inc.'s Prolia (denosumab) gained FDA approval in postmenopausal women with osteoporosis who are at high risk for fractures, and that earlier-than-expected win could bode well as the Thousand Oaks, Calif.-based firm seeks to expand denosumab in other indications. (BioWorld Today) Read More
